Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDonghua HeXHXiaoyan HanMZMingming Zhang

Discussion

Loading...

Member takes

Overview

Prospective trial demonstrates 66.7% response rate in relapsed multiple myeloma, indicating Aponermin enhances KPd efficacy.

Key Points

  • This research aims to evaluate the safety and efficacy of Aponermin combined with KPd in relapsed or refractory multiple myeloma (RRMM).
  • Prospective, open-label, multicenter study
  • Eligible patients had RRMM requiring at least 3 prior therapies
  • Prior treatments included proteasome inhibitors, IMiDs, and anti-CD38 therapy
  • Patients received Aponermin intravenously during 28-day cycles combined with KPd regimen
  • 21 patients enrolled with an overall response rate of 66.7%
  • 14% achieved very good partial response (VGPR) or better
  • Efficacy consistent across various high-risk subgroups
  • Treatment well tolerated; manageable adverse events included liver function abnormalities and tumor lysis syndrome

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4dhttps://doi.org/10.1182/blood-2025-2276
View Full Paper
Ask AI
Bookmark
Share